1. Home
  2. PRAX vs W Comparison

PRAX vs W Comparison

Compare PRAX & W Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$295.56

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Wayfair Inc.

W

Wayfair Inc.

HOLD

Current Price

$76.28

Market Cap

10.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
W
Founded
2015
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
10.0B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
PRAX
W
Price
$295.56
$76.28
Analyst Decision
Strong Buy
Buy
Analyst Count
15
28
Target Price
$572.13
$105.82
AVG Volume (30 Days)
298.8K
3.1M
Earning Date
05-01-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.15
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$7.39
Revenue Next Year
$6,395.88
$6.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$20.41
52 Week High
$354.87
$119.98

Technical Indicators

Market Signals
Indicator
PRAX
W
Relative Strength Index (RSI) 42.98 44.80
Support Level $290.36 $70.59
Resistance Level $322.32 $82.72
Average True Range (ATR) 16.81 4.36
MACD -2.42 0.91
Stochastic Oscillator 26.09 43.68

Price Performance

Historical Comparison
PRAX
W

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About W Wayfair Inc.

Wayfair engages in e-commerce in the United States (88% of 2025 sales), Canada, the United Kingdom, and Ireland. It's also embarked on expansion into the brick-and-mortar landscape, with 12 stores (excluding outlets) between the AllModern, Birch Lane, Joss & Main, and Wayfair banners. At the end of 2025, the firm offered more than 40 million products from more than 20,000 suppliers under the brands Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Its offerings include furniture, everyday and seasonal decor, decorative accents, housewares, as well as advertising and logistics services. Wayfair was founded in 2002 and began trading publicly in 2014.

Share on Social Networks: